MBV demonstrated a therapeutic effect similar to methotrexate, a standard RA therapy, by increasing the population of M2-like CD43hi/His48lo/CD206+ macrophages and reducing the secretion of pro-inflammatory chemokines CXCL10 and MCP-3, levels of which were measured in the serum of rats with acute and chronic RA [77]. Here, MRC1 is linked to rheumatoid arthritis.